Navigation Links
Research Warns of Overuse of Powerful Class of Antibiotics
Date:4/3/2011

SUNDAY, April 3 (HealthDay News) -- The use of a powerful class of antibiotics called carbapenems has increased dramatically in the United States over the past five years, a new study shows.

The increased use of these drugs -- widely regarded as the last option for treating severe infections caused by multidrug-resistant bacteria -- is cause for concern because carbapenem-resistant bacteria are becoming more common, the researchers said.

Overuse of carbapenem drugs could lead to the reduction of their effectiveness against tough-to-treat infections.

For this study, the researchers analyzed antibiotic use in 110 VA facilities from 2005 to 2009. They found a gradual rise in overall antibiotic use, but major increases in the use of certain types of antibiotics: carbapenems (102 percent); intravenous vancomycin (79 percent); and combinations of penicillin with beta-lactamase-inhibitors (41 percent).

The investigators also found that fluoroquinolones were the most frequently used class across all the VA facilities, accounting for 20 percent of all antibiotic use.

The study was to be presented Sunday at the Society for Healthcare Epidemiology of America (SHEA) annual meeting, in Dallas.

"Use of these antibiotics helps the patient receiving the treatment, but has future consequences for innocent bystanders. The more these drugs are used, the more resistance we see," study author Dr. Makoto Jones said in a society news release.

"In this era of multidrug-resistant organisms, clinicians are placed in a difficult situation," Dr. Steven Gordon, SHEA president, said in the news release. "As treatment outcomes of many bacterial infections are influenced by the timing of appropriate therapy, the increasing presence of resistant organisms triggers broader use of these powerful antibiotics for proven or suspected infections when treating patients in the hospital."

Gordon added that doctors "must always put the patient first in treatment decisions but we must empower effective antibiotic stewardship programs, infection prevention and control efforts, the development of new diagnostic testing to facilitate better treatment decisions as well as support development of new antibiotics."

Because this study was presented at a medical meeting, the data and conclusions should be viewed as preliminary until published in a peer-reviewed journal.

More information

The U.S. Centers for Disease Control and Prevention has more about antibiotics.

-- Robert Preidt

SOURCE: Society for Healthcare Epidemiology of America, news release, April 3, 2011


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. BATTLE researchers identify new biomarkers for EGFR inhibition
2. Pitt-Stanford research suggests aimless proteins crucial to disease
3. New strategic plan for NIH obesity research seeks to curb epidemic
4. Researchers need to engage lesbian, gay, bisexual, and transginder populations in health studies
5. Researchers publish molecular disease model for melanoma
6. Researchers find possible clues to tamoxifen resistance in breast cancer patients
7. UCSF researchers identify promising new treatment for childhood leukemia
8. Research explores link between asthma and smoking
9. Researchers make the leap to whole-cell simulations
10. UT Southwestern research advances fight against kidney cancer
11. Stepchildren relate to stepparents based on perceived benefits, researchers find
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Research Warns of Overuse of Powerful Class of Antibiotics
(Date:3/28/2017)... ... March 28, 2017 , ... ... the University of Pittsburgh Medical Center (UPMC) will acquire QuikClot® Bleeding Control Kits® ... The program, developed in association with efforts by the American College of Surgeons, ...
(Date:3/28/2017)... ... March 28, 2017 , ... Award-winning medical group Allied ... as new board chair for Orange County health care system CalOptima Friday. CalOptima ... soon-to-be former chair Mark Refowitz’s term, which runs through June 30 of this ...
(Date:3/28/2017)... ... March 28, 2017 , ... In its ongoing effort ... has recently developed and published an informational resource that addresses frequently asked questions. ... common inquiries the site’s team of third party administrator (TPA) contributors regularly receives ...
(Date:3/28/2017)... ... March 28, 2017 , ... ... Advanced Surgical, Inc. is thrilled to offer the recently FDA-approved Obalon Balloon System ... procedure adds to SkyLex Advanced Surgical’s already comprehensive list of weight-loss services. ...
(Date:3/28/2017)... (PRWEB) , ... March 28, 2017 , ... Oily skin is a common and unwelcomed ... Advanced Dermatology has a lot to offer to the discussion of dealing with excess ... is that there are many home remedies that can help remove the oily shine while ...
Breaking Medicine News(10 mins):
(Date:3/28/2017)... TEL AVIV, Israel , March 28, 2017 ... . This new business entity, Emosis Ltd, headquartered in ... and development of novel assays complementing the mother company existing technology ... support commercialization and sales development of Emosis kits. ... This strategic move starts building Emosis ...
(Date:3/28/2017)... , March 28, 2017  AcelRx Pharmaceuticals, ... on the development and commercialization of innovative therapies ... that the European Medicines Agency (EMA) has notified ... 30 mcg) Marketing Authorisation Application (MAA) has passed ... MAA is underway. The MAA for ARX-04 (known ...
(Date:3/28/2017)... RXi Pharmaceuticals Corporation (NASDAQ: RXII), a ... significant unmet medical needs, today announced that it ... Office (JPO) for the composition of matter of ... the treatment or prevention of fibrotic disorders, including ... retinopathy (Japanese Patent #: 6060071).  This patent includes ...
Breaking Medicine Technology: